Featured Research

from universities, journals, and other organizations

Contact lens capable of correcting hyperopia without surgery

Date:
April 22, 2010
Source:
Universitat Politècnica de Catalunya
Summary:
An innovative new contact lens developed by a Spanish researcher promises to improve the vision quality of thousands of people without surgery. The design represents the first contact lens capable of correcting hyperopia without refractive surgery by means of corneal reshaping.

The lens uses orthokeratology, a technique that reshapes the cornea to correct mild to moderate vision defects.
Credit: Image courtesy of Universitat Politècnica de Catalunya

Jaume Pauné, a graduate of the Master's Degree in Optometry and Vision Sciences at the UPC-Barcelona Tech's College of Optics and Optometry, has designed an innovative new contact lens that will improve the vision quality of thousands of people without surgery.

The Spanish Association of Opticians and Optometrists has granted its National Award to Mr. Pauné for his innovative work in this field.

Pauné's design is the first contact lens capable of correcting hyperopia without refractive surgery by means of corneal reshaping, also known as orthokeratology or ortho-K. This technique uses rigid gas-permeable contact lenses to reshape the cornea to correct vision defects such as myopia, stigmatism and mild to moderate hyperopia without surgery. Each patient is fitted with unique lenses that are custom-made for his or her eyes.

Perfect vision, without surgery

For the sake of comfort, the patient wears the contact lenses only at night. The lens works by applying pressure to the tear film that coats the outside of the cornea. This pressure changes the shape of the cornea by about 20 µm, or about half the width of a strand of human hair. In the morning, the patient removes the lenses and is able to see perfectly. The results are the same as with refractive surgery, but are temporary. These new contact lenses, developed as part of a master's thesis by Jaume Pauné, are being sold at an initial price of €1000, which includes the cost of designing unique lenses to fit each cornea, and €400 for annual replacement lenses.

The lenses are being marketed in collaboration with Atenas Vision, the distributor for Spain and Portugal, and the French laboratory Precilens, which manufactures the lenses under the name PauneLens.

Development process

Jaume Pauné developed this innovative new contact lens using existing ortho-K technology. In 2005, at an international contact lens conference in the United States, Pauné saw the presentation of the first ortho-K lens to be developed for hyperopia, which ultimately was never introduced on the market. His interest piqued, Pauné began experimenting with the idea of manufacturing such a lens. In 2008, he enrolled in the UPC-Barcelona Tech's Master's Degree in Optometry and Vision Sciences, which required him to complete a master's thesis.

In the course of his research for the thesis, he reviewed the literature and decided to design and manufacture a new model of contact lens, which he tested on ten people. One of these patients, an individual determined to find a solution to ongoing vision problems, tried six different models of the lens, each for a period of one week. With this patient, Pauné found the key to developing the first effective contact lens for hyperopia. In the process, he discovered that his technical and scientific principles were different from those of contact lens models used for myopia.


Story Source:

The above story is based on materials provided by Universitat Politècnica de Catalunya. Note: Materials may be edited for content and length.


Cite This Page:

Universitat Politècnica de Catalunya. "Contact lens capable of correcting hyperopia without surgery." ScienceDaily. ScienceDaily, 22 April 2010. <www.sciencedaily.com/releases/2010/04/100420161224.htm>.
Universitat Politècnica de Catalunya. (2010, April 22). Contact lens capable of correcting hyperopia without surgery. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100420161224.htm
Universitat Politècnica de Catalunya. "Contact lens capable of correcting hyperopia without surgery." ScienceDaily. www.sciencedaily.com/releases/2010/04/100420161224.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins